OGR1 inhibition should be investigated as a therapeutic option generally in IBD, as this pH-sensing receptor appears to sustain inflammation acting on pro-inflammatory pathways that are sensitive to inhibition by IL-10. Here, IL10 is linked to inflammatory bowel disease.